Krystal Biotech Q3 Vyjuvek gross margin 94%; sales top $1.1B since launch

Krystal Biotech reported a Q3 gross margin of 94% for Vyjuvek, with cumulative sales of the gene therapy topping $1.1 billion since launch.

Detected & updated continuously · Source: Nebula